CD30
Showing 1 - 25 of >10,000
Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)
Not yet recruiting
- Hodgkin Lymphoma
- +2 more
- Chemotherapy
- Cell infusion
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Oct 13, 2023
Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)
Recruiting
- Lymphoma
- +7 more
- ATLCAR.CD30 cells
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor Trial in Chapel Hill (ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine)
Recruiting
- Germ Cell Tumor
- Nonseminomatous Germ Cell Tumor
- ATLCAR.CD30 Cells
- +2 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 13, 2022
Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed
Not yet recruiting
- Pediatric Cancer
- +11 more
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
-
Milwaukee, WisconsinChildren's Wisconsin
Sep 14, 2022
Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)
Not yet recruiting
- Classical Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- GEN3017
- (no location specified)
Aug 25, 2023
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)
Recruiting
- Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
- Classical Hodgkin Lymphoma
- CD30.CAR-EBVST cells
-
Houston, Texas
- +1 more
Jul 20, 2022
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston
Active, not recruiting
- Anaplastic Large Cell Lymphoma
- +4 more
-
Duarte, California
- +3 more
Jul 21, 2022
Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,
Recruiting
- Recurrent Hodgkin Lymphoma
- +3 more
- Brentuximab Vedotin
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 4, 2022
Lymphoma, Relapse/Recurrence Trial in Wuhan, Nanchang (CD30 CAR-T, Camrelizumab)
Recruiting
- Lymphoma
- Relapse/Recurrence
- CD30 CAR-T
- Camrelizumab
-
Wuhan, Hubei, China
- +1 more
Apr 8, 2022
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)
Not yet recruiting
- Relapsed or Refractory Hodgkin Lymphoma
- Peripheral T Cell Lymphoma
- AFM13
- +4 more
- (no location specified)
May 30, 2023
A Study of People With CD30 Positive Lymphoma in China
Not yet recruiting
- Lymphoma
- (no location specified)
Aug 17, 2022
T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)
Withdrawn
- T Cell Lymphoma
- Brentuximab Vedotin
-
Kansas City, KansasThe University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Houston (autologous CAR.CD30 EBV specific-CTLs)
Active, not recruiting
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- autologous CAR.CD30 EBV specific-CTLs
-
Houston, Texas
- +1 more
Feb 4, 2022
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma Trial in Chapel Hill, Houston (CAR.CD30 T cells)
Active, not recruiting
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- CAR.CD30 T cells
-
Chapel Hill, North Carolina
- +2 more
Mar 16, 2022
Peripheral T Cell Lymphoma Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 T cells, Bendamustine, Fludarabine)
Recruiting
- Peripheral T Cell Lymphoma
- ATLCAR.CD30 T cells
- +3 more
-
Chapel Hill, North Carolina
- +1 more
Mar 4, 2022
Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)
Not yet recruiting
- Lymphoma
- Brentuximab Vedotin
- +3 more
-
Beijing, China
- +15 more
Jan 4, 2023
Brentuximab Vedotin Intravenous Infusion "Untreated
Active, not recruiting
- Untreated CD30-Positive Hodgkin's Lymphoma
- Brentuximab vedotin (Genetical Recombination)
-
Tokyo, JapanTakeda Selected Site
Mar 24, 2022
Hodgkin Lymphoma Trial in Valhalla (Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning)
Active, not recruiting
- Hodgkin Lymphoma
- Brentuximab Vedotin
- +2 more
-
Valhalla, New YorkNew York Medical College
Oct 24, 2022
Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory
Active, not recruiting
- Peripheral T Cell Lymphoma
- Pediatric Hodgkin Lymphoma
- Brentuximab Vedotin (Genetical Recombination)
-
Tokyo, JapanTakeda Selected Site
Oct 11, 2022
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent Trial in United States (Nivolumab, Autologous
Recruiting
- Classical Hodgkin Lymphoma
- +2 more
- Nivolumab
- +3 more
-
Duarte, California
- +4 more
Jun 27, 2022
Hodgkin Lymphoma, NK/T Cell Lymphoma, Peripheral T Cell Lymphoma, Unspecified Trial in Hangzhou (Anti CD30 CAR-T Cell Injection)
Not yet recruiting
- Hodgkin Lymphoma
- +7 more
- Anti CD30 CAR-T Cell Injection
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of medicine, Zhejiang Uni
Jan 12, 2022
CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma Trial in Houston (Brentuximab Vedotin, Laboratory Biomarker
Recruiting
- CD30-Positive Neoplastic Cells Present
- Malignant Mesothelioma
- Brentuximab Vedotin
- Laboratory Biomarker Analysis
-
Houston, TexasM D Anderson Cancer Center
Jan 3, 2022
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory Trial in United States (CD30.CAR-T, Fludarabine,
Active, not recruiting
- Hodgkin Lymphoma, Adult
- +3 more
- CD30.CAR-T
- +2 more
-
Duarte, California
- +4 more
Apr 3, 2022
Recurrent Lymphoproliferative Disorder, Refractory Lymphoproliferative Disorder Trial in Duarte (Leflunomide)
Active, not recruiting
- Recurrent Lymphoproliferative Disorder
- Refractory Lymphoproliferative Disorder
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 7, 2022
T-Cell Lymphoma Trial (Brentuximab vedotin)
Not yet recruiting
- T-Cell Lymphoma
- Brentuximab vedotin
- (no location specified)
Jun 30, 2022